Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles.

Area of Science:

• Oncology
• Biochemistry
• Materials Science

Background:

• Hyaluronic acid (HA) and cluster of differentiation 44 (CD44) interactions significantly influence the tumor microenvironment.
• These interactions promote tumor growth, angiogenesis, invasion, and metastasis.
• Targeting the HA-CD44 pathway presents a potential antitumor strategy.

Purpose of the Study:

• To develop and evaluate an innovative nanodevice for selective release of a HA-CD44 interaction inhibitor.
• To assess the efficacy and safety of the nanodevice-drug conjugate in preclinical models.

Main Methods:

• Computational analysis of the tetrahydroisoquinoline-ketone derivative (JE22) binding to CD44.
• Evaluation of cell viability, drug release efficiency, and selectivity under acidic conditions.
• Assessment of CD44 binding capacity, cell migration inhibition, and apoptotic activity.

Main Results:

• The designed nanodevice successfully released the CD44 inhibitor selectively under acidic conditions.
• JE22 demonstrated effective binding to CD44, inhibited cell migration, and induced apoptosis.
• Conjugation to the nanodevice reduced the required therapeutic dose for significant antitumor effect.

Conclusions:

• The developed nanodevice offers a promising targeted drug delivery system for antitumor therapy.
• Selective inhibition of the HA-CD44 interaction via nanodevices can enhance therapeutic efficacy and reduce dosage.
• This strategy holds potential for improving cancer treatment outcomes.